A Closer Look at Emerging Therapies in the Management of Alopecia Areata: Managed Care Considerations on JAK Inhibitors in an Evolving Treatment Landscape

A continuing medical education activity provided by NAMCP and AAMCN

Preparing for a New Era in Alopecia Areata Management: Managed Care Considerations
on the Role of New and Emerging Therapies is a three-part webinar series

This is Part 1 of the series focusing on management of Alopecia Areata

This activity is an archive from the webinar held March 24, 2021

This activity is valid from April 1, 2021 to April 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Pfizer

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.

Upon completion of this activity, participants will be able to:

  • Examine the unmet clinical needs in alopecia areata and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity

  • Assess recent pathophysiological findings in alopecia areata that have informed the study of new therapeutic targets, including JAK inhibitors

  • Analyze new evidence pertaining to the safety and efficacy of new and emerging therapies in the management of alopecia areata

  • Explore the role of emerging JAK inhibitors in the management of alopecia areata for patients in all age groups


Faculty: Brett King, MD, PhD
Associate Professor of Dermatology
Yale University School of Medicine


Brett King, MD, PhD has disclosed the following financial relationships during the past 24 months with any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Dr. King has served as a consultant for Aclairis Therapeutics Inc, Almirall, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, Prizer Inc, TWi Biotechnology Inc, Viela Bio. Dr. King as spoken for Pfizer Inc, Regeneron, and Sanofi Genzyme. This presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from Pfizer

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue